Topic Archives: Hepatitis C

Comments

  • Gr8Full!

    $EBIO just took off wow ZKSS come home! PLEASE! $ENTA np - The Chart of the Day belongs to Enanta Pharmaceutica...

  • Avatar

    Hepatitis I have known at least 10 individuals who contracted hepatitis. Of this group, two died, both in their 40’...

  • Avatar

    I 'd say Hepatitis C, as it is a chronic form of hepatitis and has a high prevalence in specific groups of people that I...

  • Avatar

    $Hepatitis D. Hepatitis D virus (HDV) is an RNA virus that was discovered in 1977 and is structurally unrelated to t...

  • Dr. KSS MD PhD

    Fine with me. Might be good to put it in a box on the face page in the new version. For this week: Which kind of virus...

  • Avatar

    $LiverFibrosis. $INLF3 "World-First Discovery Of Protein That Causes Liver Disease Brings Hope For New Treatments" ...

  • SoGiAm

    How is hepatitis C transmitted? http://www.medicalnewstoday.com/articles/318888.php AASLD 2017 In Washington - 20 to...

  • Avatar

    FDA approves Mavyret for Hepatitis C https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm...

  • Avatar

    Draft Order on Drug Prices Proposes Easing Regulations https://www.nytimes.com/2017/06/20/health/draft-order-on-drug-pr...

  • Avatar

    $RGLS: There is a urgent need amongst the medical franternity for SCY-078, deadly superbug Candida auris treatment, whil...

  • Avatar

    $HCV $GILD, $CELG Unlike its viral cousins hepatitis A and B, hepatitis C virus (HCV) has eluded the development of a...

  • Avatar

    Wide Use of New HCV (Hepatitis C) Drugs Prevents New Cases: http://www.medpagetoday.com/MeetingCoverage/CROI/63242 Di...

  • Avatar

    Interesting article - tourist's travel to Egypt for Solvadi 6K Hepatitis C Tx. Could someone with a Stat membership ple...

  • Avatar

    $GILD $RGLS W #HCV #HCC #TumorEnvironment *Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Vi...

  • Avatar

    $ACHN: Ladenburg Thalmann Dossier released today. Author: Christopher S. James, M.D. https://ladenburg.bluematrix.com/...

  • Avatar

    $RGLS On Wednesday the NYT published, "Are New Drugs for Hepatitis C Safe? A Report Raises Concerns: https://www.nyt...

  • Avatar

    Dear RGLS/Prospective investors, I hope this can appease your anxiety, over the heavy-pall smokescreen currently hangs ...

  • Avatar

    Related to this, an interesting proposal out of Forbes today advocating for the U.S government to buy Gilead to the tune...

  • Avatar

    A phase 1b of RG-101 was published in The Lancet recently: "Safety, tolerability, and antiviral effect of RG-101 in p...

  • Avatar

    This abstract more than likely moving RGLS of late. Background and aims: MicroRNA (miR)-122 is the most abundant mi...

  • Dr. KSS MD PhD

    Trouble in G-land....from WSJ last night armaceutical company’s overall profit down to $3.33 billion from $4.6 bill...

  • Avatar

    $GILD Very interesting... Here we describe a patient with advanced follicular lymphoma and concurrent hepatitis C vi...

  • Dr. KSS MD PhD

    Interesting clip from NYT: Your Surgeon Is Probably a Republican, Your Psychiatrist Probably a Democrat Margot Sange...

  • SoGiAm

    FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct...

  • Avatar

    $GILD $GSK #HIV - Barrons just published an article on this subject, quoting a Piper Jaffray's analyst who mildly refute...

  • Avatar

    Re: pharmacy benefits managers As reported by Fierce Pharma, for the third year in a row, Express Scripts unveiled a...

  • Travis Johnson, Stock Gumshoe

    In case you didn't notice, GILD ran up a little bit into earnings, then disappointed on forward guidance when they repor...

  • Avatar

    Gilead is on the cusp of a public relations debacle perhaps as big as Enron though it's anything but fishy finances so i...

  • Avatar

    RGLS I would appreciate vey much if somebody could give us an idea how long it will take to remove the clinical hold re...

  • Dr. KSS MD PhD

    Full text article from The Lancet: http://www.natap.org/2016/HCV/PIIS01406736163057972.pdf Virus hepatitis (C and B) ...

  • Avatar

    Doc, just read the news that FDS places Regulus's hepatitis C treatment on hold. Would appreciate if you can share your ...

  • Avatar

    $RGLS Regulus Therapeutics (NASDAQ:RGLS) inks a loan and security agreement with Oxford Finance LLC for up to $30M i...

  • Avatar

    GILD (not long) http://blogs.barrons.com/stockstowatchtoday/2016/06/17/gilead-sciences-a-strong-uptick-in-new-hepatitis-...

  • Avatar

    Dr. KSS: REACHMD is offering CME on co-management of Hepatitis C treatment between primary care providers and specialist...

  • Avatar

    Just this past week, a lady in our church lost a brother in his 40's due to undiagnosed Hepatitis C which turned into ca...

  • Avatar

    An estimated 3.9 million people are infected with hepatitis C in the United States. “For everyone born between 1945 a...

  • Avatar

    Long RGLS and Dr KSS. I came across a very good article in today's Pittsburgh Post-Gazette (5/5/16) Hepatitis C causing ...

  • Avatar

    Re $RGLS Listened the conference call over the weekend, and came away quite bullish over the medium term. Little disapp...

  • Avatar

    $RGLS That Dr KSS is an advisor to RGLS gives me confidence. The Fool article concludes with this: "Overall, the sell-...

  • JohnM

    $GILD - RE Merck's Zepatier Gilead Sciences: ‘Another Pretender to Hepatitis C Throne Seems to Be Suffering the Ab...

  • Dr. KSS MD PhD

    CHC is chronic hepatitis C. It's a terrible term and abbreviation, as HCV is rarely acute and virtually always becomes c...

  • Dr. KSS MD PhD

    Hepatology has long operated under the idea that the heyday of HCV was the 1960s and 1970s, That it was practices of peo...

  • Avatar

    Gilead: ''A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in dama...

  • Dr. KSS MD PhD

    Among people with HCV who are seropositive for HBV, occasional concern has been repeatedly voiced that the new oral agen...

  • JohnM

    $GILD Why One Analyst Sees Gilead Worth 66% More Argus puts a Buy on GILD with a $150 target. "In February and...

  • Avatar

    SYDNEY, Feb. 26, 2016 /PRNewswire/ -- Benitec Biopharma (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announced today that it ...

  • om

    Benitec’s Board made the decision to discontinue the hepatitis C program following a review of the co...

  • Avatar

    $RGLS Did anyone else see this or have thoughts after reading? No explanation why ALNY took this action and trying t...

  • JohnM

    $GILD Longtime Gilead Sciences CEO John Martin is stepping down and is being replaced by John Milligan, the Foster City...

  • Avatar

    $CNAT, $GNFTF Doc you wrote in http://www.stockgumshoe.com/2014/12/microblog-dawn-of-the-planet-of-the-tloglodytes/ ...

  • Avatar

    re: $GILD Fascinating NY Times Article today on overseas pricing of hepatitis C medication (sofosbuvir) and the huge i...

  • Dr. KSS MD PhD

    Serious coin to be made from this new test: A Novel HCV Antigen Test System for One-step Screening and Diagnosing Vir...

  • Dr. KSS MD PhD

    Ward/Herman editorial appearing yesterday in NEJM. Regards HCV drug costs; bottom line, they're worth it. Simple, Eff...

  • Avatar

    Enzo Biochem (ENZ) new 52wH after New York cleared Hepatitis C Test. Could be one for Dr. KSS?...

  • Gui_

    "I am not there to judge them, I am there to care for them, to care for them well" That reminds me of a comment on F...

  • JohnM

    $GILD Gilead's Sovaldi tied to slow heartbeat in hepatitis C patients By Michelle Fay Cortez Bloomberg News PO...

  • Dr. KSS MD PhD

    Study suggests unprecedented 3-week hepatitis C cure http://news.sciencemag.org/health/2015/10/study-suggests-unprecede...

  • sogiam

    $GILD- Gilead Sciences: Its Hepatitis-C Treatments Keep Getting Better http://blogs.barrons.com/stockstowatchtoday/20...

  • Avatar

    Some AbbVie news: FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viek...

  • sogiam

    BMY- Interesting about different HCV genotypes as well: NICE Recommends Daklinza (daclatasvir) for Treatment of Certai...

  • Avatar

    $RGLS Update Regulus to Present Updated Data Supporting RG-101 as Novel microRNA Therapeutic for the Treatment of H...

  • Dr. KSS MD PhD

    New paper out of the CDC "confirming" what smart hepatologists have known for 15 years. There are fools out there who ar...

  • Gui_

    Thoughts doctor, an HCV vaccine, Cambridge Biotech a legitimate contender? (Ap0logies if this co. has already been d...

  • Dr. KSS, MD PhD

    Jabber: here it is ential acquisitions get cheaper, Gilead Sciences might be a beneficiary of recent market turmoi...

  • Avatar

    Thanks for the heads up, Mr. Paglee. First we have Socialist Bernie Sanders urging the VA to scuttle GILD's hepatitis C...

  • Anamorph

    THE ANTIDOTE: INSIDE THE WORLD OF NEW PHARMA by Barry Werth (2014) In 'The Antidote,' Barry Werth picks up the stor...

  • Avatar

    $AGN - gotta like this guy... Allergan CEO says better to leave discoveries to others By Ransdell Pierson Aug 6 A...

  • Dr. KSS, MD PhD

    An impassioned post from Jules Levin, HCV treatment advocate: Compare Prices - HCV Drug Pricing vs New Cholesterol Dr...

  • Avatar

    Dr.KSS, thanks for posting this story from today's WSJ. It has a bit more about the Mayo Clinic editorial than is prin...

  • Avatar

    GILD's HEP C scripts latest data. Gilead Sciences: Does Anyone Care About Hep-C Anymore? By Ben Leviso...

  • Avatar

    New SEC filing by Benitec. Within it it states "We are developing a ddRNAi-based therapeutic, TT-034, for the treatmen...

  • Avatar

    For those who cannot open link on Baron's article. Peter Kolchinsky was 4 years old when he arrived in Milwaukee with...

  • Dr. KSS, MD PhD

    WSJ today: Rural U.S. Struggles to Combat IV Drug Abuse Hepatitis C and HIV outbreaks test public-health resources i...

  • Avatar

    Nice article on Hepatitis C. http://www.medscape.com/viewarticle/846347?src=wnl_edit_specol Cheers,Glenn...

  • Avatar

    $ESPR & $GILD Cost-Effectiveness and Affordability of New Medicines (3) The cost-effectiveness of treatments for chr...

  • DBMD

    GILD Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 2...

  • Travis Johnson, Stock Gumshoe

    In marketing terms, it looks so far like the "thunderclap" of trying to get Hepatitis C Testing Day trending on Twitter ...

  • sogiam

    ACHN-Achillion Enters Into Worldwide Collaboration For Hepatitis C With Janssen4:05 pm ET Best2ALL!-Benjamin...

  • Travis Johnson, Stock Gumshoe

    Well, the "announcement" did happen -- just doesn't mean nearly as much, in the immediate term, for any one stock as was...

  • Avatar

    hay read most of the comments. all very to the point and funny, you always know when you show interest in their speal it...

  • Avatar

    $GILD Here is a short excerpt from an article in today’s Science Dailey: “While a new generation of safer, more ef...

  • life_of_pie

    Kenny G, Thanks for the links you posted. You’re not the only one still in Benitec. Let me commiserate -- it’s no...

  • psvena

    A different perspective of $ACHN. Analyst Issues 5 Potential Biotech Buyout Candidates By Lee Jackson May 14, 2015 9:...

  • Dr. KSS, MD PhD

    The VA’s Hepatitis C Problem Newsweek By Gerard Flynn 5/9/15 at 11:00 AM http://www.newsweek.com/vas-hepatitis-c-p...

  • sogiam

    Don’t Buy Gilead’s Headline Gilead Sciences (GILD – NASDAQ) By Bottarelli Research Published Friday, May 01, 20...

  • Dr. KSS, MD PhD

    Tackling HBV in NYC, where 1/12 Asians has it. NY City Council Moves to Require Hepatitis Reporting Summary of Bil...

  • Avatar

    Re: Hepatitis C Data revealed Thursday at EASL (International Liver Congress) highlights the adverse impact of delayin...

  • Avatar

    Was surprised this hadn't been shared before but looks good for us $GILD longs. "Gilead Announces Data for Investigat...

  • Avatar

    FYI even dirk has turned on Benitec... http://www.biocqr.com/#!rss-feeds/c2t8 Time is running out for Benitec Benite...

  • Gui_

    I sure wish Dr. KSS were around, I'm sure he would give me a proper "drop and give me 20" for even posting this, howe...

  • sogiam

    ACHN-At EASL : Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, includi...

  • Avatar

    Kenny/Kris, Did you guys get this letter/ Dear joe, I am pleased to share the latest report from Lodge Partners i...

  • sogiam

    GILD-M&A soon maybe? Gilead More Open to Deals -- Market Talk 4/3/15 4:46 PM ET (Dow Jones) -- Gilead (GILD) Chief Oper...

  • psvena

    $GILD The FDA accepts for review Bristol-Myers Squibb's (BMY +1.6%) resubmitted New Drug Application (NDA) for daclatas...

  • Avatar

    Motley Fool Morning Headline: "Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?" htt...

  • Avatar

    RE:GILD – good news from Barron’s. Long GILD. RBC’s Michael Yee and team think AbbVie’s (ABBV) update on its he...

  • Avatar

    Could this be part of the reason for Gild going sideways. This seems goofy. Widespread hepatitis C screening - do ben...

  • Avatar

    GILD expands Hepatitis C Generic Licensing Agreements. http://finance.yahoo.com/news/gilead-expands-hepatitis-c-generic...

  • Avatar

    Here's the Barrons comment on GILD--- Gilead Sciences: Gilead Sciences won us over after last week’s 14% plunge in i...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch